Michael Gerometta

410 total citations
16 papers, 190 citations indexed

About

Michael Gerometta is a scholar working on Radiology, Nuclear Medicine and Imaging, Internal Medicine and Molecular Biology. According to data from OpenAlex, Michael Gerometta has authored 16 papers receiving a total of 190 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Internal Medicine and 4 papers in Molecular Biology. Recurrent topics in Michael Gerometta's work include Venous Thromboembolism Diagnosis and Management (6 papers), Retinal Diseases and Treatments (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Michael Gerometta is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (6 papers), Retinal Diseases and Treatments (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Michael Gerometta collaborates with scholars based in Australia, United States and Belgium. Michael Gerometta's co-authors include David Macfarlane, Richard Smart, Timothy A. Morris, Paul R. Eisenberg, Wendy Tsui, Andrew M. Scott, R Konopka, Philip J. Hogg, Peter Bundesen and Péter Schmidt and has published in prestigious journals such as Biochemistry, American Journal of Respiratory and Critical Care Medicine and Scientific Reports.

In The Last Decade

Michael Gerometta

16 papers receiving 185 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Gerometta Australia 9 80 61 50 31 29 16 190
Kashyap Patel United States 12 153 1.9× 196 3.2× 18 0.4× 14 0.5× 44 1.5× 32 372
Hikmet Hasıripi Türkiye 14 292 3.6× 21 0.3× 11 0.2× 390 12.6× 32 1.1× 29 505
Xiaoyan He China 11 31 0.4× 60 1.0× 4 0.1× 18 0.6× 25 278
Roberto Assandri Italy 9 21 0.3× 71 1.2× 2 0.0× 2 0.1× 7 0.2× 23 230
Feimei Liu United States 7 69 0.9× 113 1.9× 71 2.3× 6 0.2× 10 452
Amichai Schattner Israel 7 56 0.7× 49 0.8× 3 0.1× 22 0.8× 17 278
Agnieszka Kubicka‐Trząska Poland 11 152 1.9× 50 0.8× 3 0.1× 268 8.6× 8 0.3× 65 331
Eleni K. Konstantinou United States 10 61 0.8× 93 1.5× 1 0.0× 123 4.0× 15 0.5× 23 268
H-P Hartung Germany 9 47 0.6× 37 0.6× 5 0.2× 45 1.6× 10 330
Machteld I. Bosscha Netherlands 9 66 0.8× 47 0.8× 122 3.9× 3 0.1× 18 237

Countries citing papers authored by Michael Gerometta

Since Specialization
Citations

This map shows the geographic impact of Michael Gerometta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Gerometta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Gerometta more than expected).

Fields of papers citing papers by Michael Gerometta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Gerometta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Gerometta. The network helps show where Michael Gerometta may publish in the future.

Co-authorship network of co-authors of Michael Gerometta

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Gerometta. A scholar is included among the top collaborators of Michael Gerometta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Gerometta. Michael Gerometta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Leitch, Ian M., Michael Gerometta, David Eichenbaum, et al.. (2024). Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review. Ophthalmology and Therapy. 13(7). 1857–1875. 8 indexed citations
2.
Gerometta, Michael, Robert D. Henderson, Leanne Cooper, et al.. (2024). Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study. Clinical Drug Investigation. 45(1). 17–28. 1 indexed citations
3.
Jackson, Timothy L., Jason S. Slakter, Marc Buyse, et al.. (2023). A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration. Ophthalmology. 130(6). 588–597. 32 indexed citations
4.
Pegg, Cassandra L., Leanne Cooper, Jing Zhao, et al.. (2017). Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Scientific Reports. 7(1). 6519–6519. 14 indexed citations
5.
6.
Chiu, Joyce, Jason W.H. Wong, Michael Gerometta, & Philip J. Hogg. (2013). Mechanism of Dimerization of a Recombinant Mature Vascular Endothelial Growth Factor C. Biochemistry. 53(1). 7–9. 17 indexed citations
7.
Morris, Timothy A., Michael Gerometta, Roger D. Yusen, et al.. (2011). Detection of Pulmonary Emboli With 99mTc-Labeled Anti–D-dimer (DI-80B3)Fab′ Fragments (ThromboView). American Journal of Respiratory and Critical Care Medicine. 184(6). 708–714. 17 indexed citations
8.
Morris, Timothy A., Michael Gerometta, Richard Smart, et al.. (2011). Pulmonary Emboli Imaging with 99mTc-labelled Anti-D-dimer (DI-80B3) Fab′ Followed by SPECT. Heart Lung and Circulation. 20(8). 503–511. 7 indexed citations
9.
Macfarlane, David, Paul R. Eisenberg, George Larcos, et al.. (2008). Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab′ fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial. European Journal of Nuclear Medicine and Molecular Imaging. 36(2). 250–259. 16 indexed citations
10.
Douketis, J., JoAnne Julian, Jody Ginsberg, et al.. (2007). EVALUATION OF THE ACCURACY OF A 99MTC-LABELLED MONOCLONAL ANTIBODY SPECIFIC FOR D-DIMER IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS (DVT). Journal of Thrombosis and Haemostasis. 5. P–S. 1 indexed citations
11.
Morris, Timothy A., David Macfarlane, Richard Eisenberg, Richard Smart, & Michael Gerometta. (2007). SENSITIVITY AND SAFETY OF PULMONARY EMBOLI IMAGING WITH RADIOLABELED ANTI-D-DIMER MONOCLONAL ANTIBODY FRAGMENTS. Journal of Thrombosis and Haemostasis. 5. O–T. 1 indexed citations
12.
Macfarlane, David, Richard Smart, Wendy Tsui, et al.. (2006). Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′. European Journal of Nuclear Medicine and Molecular Imaging. 33(6). 648–656. 17 indexed citations
13.
Morris, Timothy A., David Macfarlane, Paul R. Eisenberg, Richard Smart, & Michael Gerometta. (2006). CLINICAL DIAGNOSTIC IMAGING OF PULMONARY EMBOLI USING RADIOLABELED ANTICROSSLINKED FIBRIN ANTIBODIES (THROMBOVIEW®). CHEST Journal. 130(4). 275S–275S. 3 indexed citations
14.
Morris, Timothy A., James J. Marsh, Peter G. Chiles, et al.. (2004). Single Photon Emission Computed Tomography of Pulmonary Emboli and Venous Thrombi Using Anti–D-Dimer. American Journal of Respiratory and Critical Care Medicine. 169(9). 987–993. 26 indexed citations
15.
Wilson, Kim, Michael Gerometta, Dennis B. Rylatt, et al.. (1991). Rapid whole blood assay for HIV-1 seropositivity using an Fab-peptide conjugate. Journal of Immunological Methods. 138(1). 111–119. 24 indexed citations
16.
Bundesen, Peter, S. Martin, Gordon H. Dixon, et al.. (1990). An evaluation of the VetREDTM canine heartworm antigen test.. 20(3). 144–149. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kashyap Patel Breakdown of academic impact, for papers by Hikmet Hasıripi Breakdown of academic impact, for papers by Xiaoyan He Breakdown of academic impact, for papers by Roberto Assandri Breakdown of academic impact, for papers by Feimei Liu Breakdown of academic impact, for papers by Amichai Schattner Breakdown of academic impact, for papers by Agnieszka Kubicka‐Trząska Breakdown of academic impact, for papers by Eleni K. Konstantinou Breakdown of academic impact, for papers by H-P Hartung Breakdown of academic impact, for papers by Machteld I. Bosscha
Rankless by CCL
2026